Compare Quest Diagnostics Inc (DGX) vs Elastic NV (ESTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Elastic NV — how do they compare? Quest Diagnostics Inc trades at $237.96 (market cap $26.21B), while Elastic NV trades at $76.69 (market cap $7.94B). The key difference: Quest Diagnostics Inc is far larger — about 3.3× Elastic NV's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| DGX | ESTC | |
|---|---|---|
Market Cap | $26.21B | $7.94B |
Sector | Health | Technology |
52-Week High | $238.50 | $94.47 |
52-Week Low | $173.49 | $43.30 |
Enterprise Value | $31.97B | $7.16B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Elastic (ESTC) trades at $75.88, down 0.58% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. Recent earnings beats and a projected net profit margin of 21.14% for 2026 highlight improving fundamentals, while collaborations with OpenAI and AWS security distinctions underscore strategic growth. The stock faces headwinds from high valuation multiples and a negative net income in 2025.
The outlook remains positive given analyst consensus and product innovations, but risks include elevated P/E and EV/EBITDA ratios, potential legal scrutiny, and competitive pressures. Upside is supported by a $106 high price target, though investor caution is warranted near-term due to overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
